RegistrAME: the Spanish self-reported patient registry of spinal muscular atrophy

Other authors

Institut Català de la Salut

[Cattinar MG] Fundación Atrofia Muscular Espinal España (FundAME), Madrid, Spain. [de Lemus M] Fundación Atrofia Muscular Espinal España (FundAME), Madrid, Spain. SMA Europe, Freiburg, Germany. Committee of Advanced Therapies at the European Medicines Agency, Amsterdam, The Netherlands. [Tizzano E] Grup de Recerca de Medicina Genètica, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Àrea de Genètica Clínica i Molecular, Vall d’Hebron Hospital Universitari, Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2024-02-23T14:07:09Z

2024-02-23T14:07:09Z

2024-02-19



Abstract

Patient registry; Self-reported registry; Spinal muscular atrophy


Registre de pacients; Registre autoinformat; Atròfia muscular espinal


Registro de pacientes; Registro autoinformado; Atrofia muscular espinal


Background Spinal Muscular Atrophy (SMA) is a rare neuromuscular disorder characterized by progressive degeneration of motor neurons and muscle weakness resulting in premature death or severe motor disability. Over the last decade, SMA has dramatically changed thanks to new advances in care and the emergence of disease-specific treatments. RegistrAME is a self-reported specific disease registry with an accurate curation system. It has collected data on SMA patients in Spain since 2015, gathering demographic, clinical, and patient-reported outcome data, all of which are patient-relevant. RegistrAME is part of the TREAT NMD network. This study aims to describe the advantages and disadvantages of a self–reported SMA registry, as well as the different variables of interest in the health status of RegistrAME patients. Results In total, 295 living patients with a confirmed diagnosis of SMA-5q were included (aged 1 to 77 years; mean 20.28). Half of the patients (50.2%) were ≥ 16 years old; 22.03% were type 1, 48.47% were type 2, 28.82% were type 3, and 0.7% were type 4. All functional statuses (non-sitter, sitter, and walkers) could be observed in each SMA type. Adult patients harbored the least aggressive SMA types, however, they presented the greatest level of disability. Patients with SMA type 1 had scoliosis surgery about five years earlier than patients with SMA type 2. None of the type 1 patients who achieved ambulation were wheelchair-free outdoors. This was also evident in 62.5% of type 2 walker patients and 44% of type 3 walker patients. Of the SMA type 1 patients, 40% had a gastrostomy (of which 84% had two SMN2 copies). One in five children with SMA type 1 (one to seven years of age) were ventilation-free. Conclusions The information provided by RegistrAME in a “real-world” setting allows better management of family expectations, an adequate approach to the disease and patients’ needs, as well as a better understanding of the impact of the disease. It also helps monitor the evolution of care, which will result in the need for updated guidelines.


Funding for this project was provided by FundAME.

Document Type

Article


Published version

Language

English

Publisher

BMC

Related items

Orphanet Journal of Rare Diseases;19

https://doi.org/10.1186/s13023-024-03071-7

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)